Advancing information highlight retatrutide, a dual activator for GLP-1R and GIPR, reveal encouraging potential in addressing obesity and associated disease states. Preliminary testing show considerable fat reduction https://retatrutideresearchlab.co.uk/product-category/pharmaceutical-research-reference/